Neoadjuvant Chemotherapy (NC) Should Be Administered to Fit Patients With Newly Diagnosed, Potentially Resectable Muscle-Invasive Urothelial Cancer (MIUC) of the Bladder – A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process

Canadian Urological Association Journal - Canada

doi 10.5489/cuaj.1506